WASHINGTON — President Joe Biden, relaunching the “cancer moonshot” he headed during the Obama administration, announced Wednesday a multipronged effort to bolster prevention, screening and research, with the goal of reducing the death rate from the disease by 50% during the next 25 years.
The initiative, detailed by Mr. Biden at a White House gathering attended by about 100 cancer researchers, advocates and patients, and several members of Congress, represents a reboot of the project Mr. Biden and his wife, Jill, embraced after the death of their 46-year-old son, Beau, from brain cancer in 2015. Mr. Biden was vice president at the time.
The meeting Wednesday included emotional remarks by Ms. Biden and Vice President Kamala Harris, whose mother was a cancer researcher and died of the disease.
“All those we lost, all those we miss, we can end cancer as we know it,” the president said. “This is a presidential White House priority. Period.”
The moonshot reboot features a long list of goals. The plan includes urging Americans to resume cancer screening, to make up for the millions of tests missed during the coronavirus pandemic — something that Ms. Biden will be heavily involved in. It also calls for more equitable access to care — providing, for example, mobile screening to make it easier for patients to get the tests.
One thing the project doesn’t have: plans on how to pay for it.
“The goals are clear and important, but what’s not clear is how we get there,” said a cancer advocate who spoke on the condition of anonymity to avoid the ire of the White House. “Where are the dollars coming from?”
Mr. Biden, in his comments, called on Congress to fund the effort, without providing a specific proposal. He also urged lawmakers to come up with money for his previously proposed advanced research agency to propel breakthrough medical treatments for cancer, diabetes, Alzheimer’s and other life-threatening diseases. Talks with lawmakers are underway on that issue.
Some cancer advocates said they would press the president to lay out concrete funding proposals in his State of the Union address, scheduled for March 1.
Congress provided $1.8 billion for the 2016 moonshot, parceled out over seven years. Two years of funding remains, totaling about $400 million. Cancer advocates worry that without a substantial infusion of money, cancer efforts, including those of the National Cancer Institute, could be hampered.
Margaret Foti, chief executive officer of the American Association for Cancer Research, praised the new cancer initiative, saying increased prevention and early detection efforts could greatly reduce death rates. But developing such improvements are costly, she added, saying, “We need to make sure there’s funding available to develop the new technologies and implement them.”
The cancer blueprint calls for a “cancer cabinet” of officials from across the federal government to coordinate activities, and for the speedup of emerging early detection approaches such as liquid biopsies to find multiple cancers through blood tests.
Mr. Biden, as vice president and as a 2020 presidential candidate, sometimes talked about curing cancer but has since reverted to more measured language. A year ago, during a visit to a coronavirus vaccine manufacturing facility in Michigan belonging to the drugmaker Pfizer, Mr. Biden said, “I want you to know that, once we beat COVID, we’re going to do everything we can to end cancer as we know it.”
Mr. Biden on Wednesday called the central goal of his plan — to cut the mortality rate for cancer by 50% during the next 25 years — “ambitious but doable.” He noted that the death rate has fallen by about 25% in the past 20 years. That improvement in large part reflects a sharp reduction in tobacco use, but also the impact of new treatments, including immunotherapy and precision medicines.
Some cancer experts said the goal of a 50% reduction was too modest and called for a more aggressive target. But Deb Schrag, an oncologist at Memorial Sloan Kettering Cancer Center, said the White House goal was appropriate. At some point, she argued, the decline in tobacco use might slow. At the same time, cancers related to obesity, such as uterine and pancreatic malignancies, are expected to continue to rise or, at best, plateau.
“We don’t have a good solution for obesity,” she said.
Some cancer experts welcomed what they called a more realistic view of the cancer challenge.
“We have had some disappointment with overly ambitious goals,” said Clifford Hudis, chief executive of the American Society of Clinical Oncology. “I think realism and maybe even over-delivering is better.”
But others said many of the steps described by the White House are not new and called for much more far-reaching efforts to defeat a disease that kills more than 600,000 Americans a year.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.